Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
517 stopped studies mapped to Malignant Liver Neoplasm and descendants · 92% state a reason
Over the 517 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02087878 | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel…(HSTCL) | — | withdrawn | Mar 14, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With… | Phase 1 | withdrawn | Nov 11, 2014 | University of Hawaii | Closed due to no accrual | Enrollment / accrual |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment… | N/A | terminated | Dec 23, 2014 | Istituto Clinico Humanitas | too slow enrollment | Enrollment / accrual |
| NCT02102971 | Observational Study of Biomarker During Liver Surgery | — | terminated | Apr 3, 2014 | University of Florida | Expired with UF IRB. | Other (stated, no rule matched) |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | Phase 1 | withdrawn | Nov 13, 2018 | Lee's Pharmaceutical Limited | Sponsor's commercial decision | Other (stated, no rule matched) |
| NCT02147301 | TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve | N/A | terminated | May 26, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of… | Phase 2 | withdrawn | Oct 27, 2016 | Shanghai Proton and Heavy Ion Center | enrollment was too slow | Enrollment / accrual |
| NCT01817205 | Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular… | N/A | terminated | Mar 25, 2013 | Chinese University of Hong Kong | poor case accrual | Enrollment / accrual |
| NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients…(DCE-MRI) | Phase 4 | terminated | Mar 7, 2013 | Guerbet | The planned number of enrolled patients was not reached. | Enrollment / accrual |
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With…(ORIENTAL) | Phase 3 | terminated | Nov 4, 2011 | Taiho Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | Phase 1 | terminated | Nov 21, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd. | Will study new T-cell construct for the same indication | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin…(LD-FOX4/HCC) | Phase 2 / Phase 3 | withdrawn | Aug 19, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for… | Phase 2 / Phase 3 | withdrawn | Aug 27, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy… | Phase 2 / Phase 3 | withdrawn | Oct 22, 2015 | Guangxi Medical University | not stated | Not stated |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | Phase 2 | withdrawn | Apr 18, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing… | N/A | withdrawn | Oct 3, 2017 | University of Southern California | Accrual issue | Enrollment / accrual |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With… | N/A | terminated | Feb 7, 2011 | University of California, San Francisco | Off study clinical use of Y90 glass microspheres (TheraSphere) | Other (stated, no rule matched) |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | Phase 2 | withdrawn | Dec 14, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | Phase 2 | withdrawn | Dec 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | Phase 2 | withdrawn | Jan 14, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | Phase 3 | withdrawn | Nov 16, 2018 | Sun Yat-sen University | No paritcipants enrolled | Enrollment / accrual |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | Phase 2 | withdrawn | Dec 20, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven… | Phase 3 | withdrawn | Jan 3, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | Phase 2 | withdrawn | Nov 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | Phase 3 | terminated | Aug 30, 2012 | Rennes University Hospital | insufficient recruitment | Enrollment / accrual |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary… | Phase 2 | terminated | Oct 31, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Oct 17, 2014 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication | Other (stated, no rule matched) |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | — | terminated | Apr 25, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding due to difficulty with recruitment and participant retention. | Enrollment / accrual |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With… | N/A | terminated | Apr 22, 2016 | Fudan University | The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose… | Enrollment / accrual |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous… | Phase 4 | terminated | May 16, 2012 | Sun Yat-sen University | not stated | Not stated |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a… | Phase 2 / Phase 3 | terminated | Aug 19, 2014 | Sun Yat-sen University | protocol violation | Other (stated, no rule matched) |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein… | Phase 1 / Phase 2 | terminated | Jan 27, 2017 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication. | Other (stated, no rule matched) |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | — | terminated | Jun 1, 2016 | The University of Texas Health Science Center, Houston | PI transferred to another institution and did not take this study with him. | Other (stated, no rule matched) |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
| NCT02599909 | Gut Microbiota in People With Hepatocellular Carcinoma (HCC) | — | withdrawn | Nov 9, 2015 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02967523 | Surefire Precision Infusion System Registry | — | terminated | Nov 18, 2016 | Surefire Medical, Inc. | not stated | Not stated |
| NCT03345225 | A Clinical Study of Precision TACE (P-TACE) With Surefire | N/A | withdrawn | Nov 17, 2017 | University of Miami | Funding | Funding |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced… | Phase 1 / Phase 2 | terminated | Aug 30, 2011 | Taiwan Liposome Company | not stated | Not stated |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Phase 2 | withdrawn | Dec 13, 2013 | Children's Oncology Group | IND no longer available. | Other (stated, no rule matched) |
| NCT02057874 | 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | N/A | terminated | Feb 7, 2014 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | Phase 2 | terminated | Jan 30, 2009 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT03168152 | Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for… | N/A | withdrawn | May 30, 2017 | University of Michigan Rogel Cancer Center | No patients were accrued to the trial | Enrollment / accrual |
| NCT02748161 | DEB-TACE for Hepatocellular Carcinoma(QED) | N/A | terminated | Apr 22, 2016 | Surefire Medical, Inc. | Low enrollment | Enrollment / accrual |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow… | Phase 2 | withdrawn | Mar 9, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | This study was withdrawn due to lack of necessary resources from the liver transplant surgical… | Other (stated, no rule matched) |
| NCT02690350 | An Open Study Assessing the Safety and Tolerability of U3-1784 | Phase 1 | terminated | Feb 24, 2016 | Daiichi Sankyo | Program discontinued for business reasons (not safety). | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 22, 2019source: clinicaltrials